Jul 2026· International Journal of Biology and Life Sciences· 0 citations· 26 references
TL;DR
The composition of core functions of the component of LNPs, molecular evolution trajectory, targeting optimization and so on, and the latest research progress of LNP in targeted delivery of traditional chemotherapeutic agents, specific gene regulation by nucleic acid therapy and combination cancer therapy etc are summarized.
Abstract
Malignant tumors, featuring strong heterogeneity, innate immune escape and acquired drug resistance, is the top cause of disease-related death worldwide. Traditional treatments for these cancers have serious drawbacks in terms of therapeutic efficacy and safety. Lipid nanoparticle (LNP) is the most powerful nonviral nucleic acid delivery vector to date and can achieve efficient encapsulation, protection and intracellular delivery of nucleic acid molecules with a biomimetic nanostructure interlinked synergistically assembled by core components, has become a key research vehicle in the field of cancer gene therapy. In this review, we summarize the composition of core functions of the component of LNPs, molecular evolution trajectory, targeting optimization and so on, and system summarize the latest research progress of LNP in targeted delivery of traditional chemotherapeutic agents, specific gene regulation by nucleic acid therapy and combination cancer therapy etc. Collectively, these pieces of work provide a complete academic reference for future fundamental studies and clinical translation of LNP-mediated cancer gene therapy technologies, and lay the theoretical basis for further non-viral nucleic acid vectors used in cancer gene therapy in the wider biomedical field.
The high resistance to therapy, molecular heterogeneity, early metastasis, and quick drug resistance make triple-negative breast cancer (TNBC) difficult and even impossible to treat. The conventional chemotherapy is highly toxic, not specifically targeting the tumor, and has limited efficacy, so more sophisticated delivery mechanisms are required. To overcome these shortcomings, lipid nanotechnology is provided as a controlled, targeted, and multifunctional drug delivery system. This review outlines the recent developments of lipid nanoparticles for TNBC, including liposomes, solid lipid nanoparticles, nanostructured lipid carriers, lipidpolymer hybrids, ionizable lipid nanoparticles, and biomimetic vesicles. These systems enable improved tumor targeting and delivery of chemotherapeutics, gene editing agents, and combination therapeutics. Rational design, targeting strategies, modulation of the tumor microenvironment, targeting cancer stem cells, and breaking multidrug resistance are highlighted. Pharmacokinetic, safety, manufacturing, regulatory, and translational issues are discussed, along with pre-clinical and emerging clinical evidence. Lastly, future directions are suggested to help develop modular, precise, and clinically scalable lipid nanoparticle systems for effective management of TNBC.
Issac V. Cherian, Harpreet Kaur, Kamre Aalam et al.· Nano LIFE· 0 citations
A translational framework for overcoming key barriers in pharmaceutical intervention design for oncology applications is outlined, integrating drug delivery engineering, molecular biopharmaceutics, and computational optimization.
Manoj Dalabehera, Shubham K. Chaudhari, Jatin Kumar et al.· Journal of Pharmacy and Scie...· 0 citations
Despite their promise, significant challenges remain, including low cargo-loading efficiency, batch heterogeneity, limited scalability and the absence of standardized manufacturing and regulatory frameworks, future research must address these barriers to accelerate the clinical translation of exosome-based therapeutics.
Elza Karabagh, Babek Alibayov, Adil Allahverdiyev· Expert Reviews in Molecular...· 0 citations
Colon cancer (CC) is a leading cause of cancer-related mortality worldwide, and its poor prognostic outcome can be attributed to factors such as late diagnosis, tumor heterogeneity, and the failure of conventional chemotherapeutic therapies. Biomimetic nanomaterials that can mimic biological behaviors have recently generated transformative drug carriers with higher biocompatibility, evasion of the immune system, and tumor-seeking capabilities. In this review, recent progresses in biomimetic systems are summarized, such as cell membrane-coated nanoparticles, exosome-based carriers, and ligand-modified nanostructures, with a particular focus on their design paradigm and drug delivery mechanisms and the therapeutic potentiality in CC. Although preclinical investigations reveal potential response, translational barriers to clinical application remain considerable including but not limited to scalability in nanomaterial manufacturing, batch variability in produced materials, and regulatory challenges under FD/EMA regulation. Possible solutions involve cost-effective and scalable macrofluidic and automated bioreactor technologies, comprehensive protocols of exosome isolation and nanoparticle characterization, and systemic harmonization with regulatory frameworks for safety and quality at a stage earlier than the end of the process. Future directions towards combining biomimetic nanocarriers with gene-editing tools, immunotherapies, and phytochemical-based agents for synergistic effects, and the development of novel theranostic systems integrating diagnosis and treatment will be pursued. Overcoming these translational hurdles and interdisciplinary collaborations are critical for biomimetic nanomaterials to fulfil their huge potential to move colon cancer therapy closer to a safer, more effective and clinically practicable reality.
The recent developments, therapeutic applications, challenges, and future perspectives of Nanoparticle based cancer drug delivery systems are summarized.
H. G, M. K., R. Palaniswamy· International Journal of Cur...· 0 citations
Nanoparticle‐based therapies are a unique new frontier in breast cancer therapy, have considerable clinical potential, offer promise for patient‐specific treatment, and warrant further investigation in breast cancer, particularly in advanced targeting mechanisms, multifunctional approaches, and individualized interventions.
Sina M Matalqah, Laila M Matalqah, Abdel Rahman Al Tawaha et al.· International Journal of Bre...· 3 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
